Corey J Lager1, Nazanene H Esfandiari1, Yingying Luo2, Angela R Subauste3, Andrew T Kraftson1, Morton B Brown4, Oliver A Varban5, Rasimcan Meral1, Ruth B Cassidy5, Catherine K Nay1, Amy L Lockwood1, Darlene Bellers1, Colleen M Buda5, Elif A Oral6. 1. Division of Metabolism, Endocrinology, and Diabetes, Brehm Center for Diabetes, Michigan Medicine, 24 Frank Lloyd Wright Drive, Domino's Farm, Lobby C, Ann Arbor, MI, 48106, USA. 2. Department of Endocrinology, Peking University People's Hospital, No. 11, Xizhimen South Street, Xicheng District, Beijing, 100044, China. 3. Division of Endocrinology, University of Mississippi, 2500 N State St, Jackson, MS, 39216, USA. 4. School of Public Health, University of Michigan, 1415 Washington Heights, Ann Arbor, MI, 48109, USA. 5. Division of Minimally Invasive Surgery, Department of General Surgery, Michigan Medicine, 1500 E Medical Center Dr, Ann Arbor, MI, 48109, USA. 6. Division of Metabolism, Endocrinology, and Diabetes, Brehm Center for Diabetes, Michigan Medicine, 24 Frank Lloyd Wright Drive, Domino's Farm, Lobby C, Ann Arbor, MI, 48106, USA. eliforal@umich.edu.
Abstract
BACKGROUND: Sleeve gastrectomy (LSG) is now the predominant bariatric surgery performed, yet there is limited long-term data comparing important outcomes between LSG and Roux-en-Y gastric bypass (RYGB). This study compares weight loss and impact on comorbidities of the two procedures. METHODS: We retrospectively evaluated weight, blood pressure, hemoglobin A1c, cholesterol, and medication use for hypertension, diabetes, and hyperlipidemia at 1-4 years post-operatively in 380 patients who underwent RYGB and 334 patients who underwent LSG at the University of Michigan from January 2008 to November 2013. Follow-up rates from 714 patients initially were 657 (92%), 556 (78%), 507 (71%), and 498 (70%) at 1-4 years post-operatively. RESULTS: Baseline characteristics were similar except for higher weight and BMI in LSG. There was greater weight loss with RYGB vs. LSG at all points. Hemoglobin A1c and total cholesterol improved more in RYGB vs. LSG at 4 years. There was greater remission of hypertension and discontinuation of all medications for hypertension and diabetes with RYGB at 4 years. CONCLUSIONS: Weight loss, reduction in medications for hypertension and diabetes, improvements in markers of diabetes and hyperlipidemia, and remission rates of hypertension were superior with RYGB vs. LSG 4 years post-operatively. Choice of bariatric procedures should be tailored to surgical risk, comorbidities, and weight loss goals.
BACKGROUND: Sleeve gastrectomy (LSG) is now the predominant bariatric surgery performed, yet there is limited long-term data comparing important outcomes between LSG and Roux-en-Y gastric bypass (RYGB). This study compares weight loss and impact on comorbidities of the two procedures. METHODS: We retrospectively evaluated weight, blood pressure, hemoglobin A1c, cholesterol, and medication use for hypertension, diabetes, and hyperlipidemia at 1-4 years post-operatively in 380 patients who underwent RYGB and 334 patients who underwent LSG at the University of Michigan from January 2008 to November 2013. Follow-up rates from 714 patients initially were 657 (92%), 556 (78%), 507 (71%), and 498 (70%) at 1-4 years post-operatively. RESULTS: Baseline characteristics were similar except for higher weight and BMI in LSG. There was greater weight loss with RYGB vs. LSG at all points. Hemoglobin A1c and total cholesterol improved more in RYGB vs. LSG at 4 years. There was greater remission of hypertension and discontinuation of all medications for hypertension and diabetes with RYGB at 4 years. CONCLUSIONS: Weight loss, reduction in medications for hypertension and diabetes, improvements in markers of diabetes and hyperlipidemia, and remission rates of hypertension were superior with RYGB vs. LSG 4 years post-operatively. Choice of bariatric procedures should be tailored to surgical risk, comorbidities, and weight loss goals.
Authors: David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman Journal: N Engl J Med Date: 2005-12-22 Impact factor: 91.245
Authors: Konstantinos Spaniolas; Kevin R Kasten; Jason Brinkley; Megan E Sippey; Anthony Mozer; William H Chapman; Walter J Pories Journal: Obes Surg Date: 2015-08 Impact factor: 4.129
Authors: Xuanping Zhang; Edward W Gregg; David F Williamson; Lawrence E Barker; William Thomas; Kai McKeever Bullard; Giuseppina Imperatore; Desmond E Williams; Ann L Albright Journal: Diabetes Care Date: 2010-07 Impact factor: 19.112
Authors: Chun Shing Kwok; Ashish Pradhan; Muhammad A Khan; Simon G Anderson; Bernard D Keavney; Phyo Kyaw Myint; Mamas A Mamas; Yoon K Loke Journal: Int J Cardiol Date: 2014-02-24 Impact factor: 4.164
Authors: Christopher D Still; G Craig Wood; Xin Chu; Christina Manney; William Strodel; Anthony Petrick; Jon Gabrielsen; Tooraj Mirshahi; George Argyropoulos; Jamie Seiler; Marco Yung; Peter Benotti; Glenn S Gerhard Journal: Obesity (Silver Spring) Date: 2014-02-06 Impact factor: 5.002
Authors: Corey J Lager; Nazanene H Esfandiari; Angela R Subauste; Andrew T Kraftson; Morton B Brown; Ruth B Cassidy; Catherine K Nay; Amy L Lockwood; Oliver A Varban; Elif A Oral Journal: Obes Surg Date: 2017-01 Impact factor: 4.129
Authors: Andrew Kraftson; Anne H Cain-Nielsen; Amy Lockwood; Yingying Luo; Colleen Buda; Corey Lager; Nazanene H Esfandiari; Elif Oral; Oliver A Varban Journal: Obes Surg Date: 2022-10-18 Impact factor: 3.479
Authors: J Marvin Soeder; Julia Luthardt; Michael Rullmann; Georg A Becker; Mohammed K Hankir; Marianne Patt; Philipp M Meyer; Tatjana Schütz; Yu-Shin Ding; Anja Hilbert; Arne Dietrich; Osama Sabri; Swen Hesse Journal: Obes Surg Date: 2021-08-19 Impact factor: 3.479